Table 3.
A summary of vaccines that have been validated in clinical trials in children
| Vaccine name (developer) | BNT162b2 (Pfizer/BioNTech)77,78 | mRNA‐1273 (Moderna)79 | CoronaVac (Sinovac)80 | BBIBP‐CorV (Sinopharm)81 | Ad5‐nCoV (CanSino Biologics)82 | ZyCov‐D (Cadila Healthcare)83* |
|---|---|---|---|---|---|---|
| Vaccine type | mRNA vaccine | mRNA vaccine | Inactivated vaccine | Inactivated vaccine | Adenovirus vaccine | DNA vaccine |
| Age range | 5–15 | 12–17 | 3–17 | 3–17 | 6–17 | 12–17 |
| Location | USA, Spain, Finland, Poland | USA | China | China | China | India |
| Dose of administration |
5–11 years: 10 μg/dose 12–15 years: 30 μg/dose |
100 μg/dose | 1.5 or 3 μg/dose | 2 μg, 4 μg, or 8 μg/dose | 0.3 ml/dose | 2 mg/dose |
| Number of scheduled doses | First and second dose (0, 21 days) | First and second dose (0, 28 days) | First and second dose (0, 28 days) | First, second, and third dose (0, 28, and 56 days) | First and second dose (0, 56 days) | First, second, and third dose (0, 28, and 56 days) |
| Vaccine efficacy |
5–11 years: 90.7% (after second dose) 12–15 years: 100% (after second dose) |
93.3% (after second dose) | N/A | N/A | N/A | 66.6% (after first dose), 100% (after two dose) |
| Immune response | 99.2% serologic response | 98.8% serologic response | Over 96.8% serologic response | 100% serologic response | 98%-100% serologic response | 93.33% serologic response at day 84 |
| Adverse reaction | Injection site pain, fatigue, headache, and fever | Injection site pain, headache, and fatigue | Injection site pain, and fever | Fever, and cough | Fever, headache, fatigue, injection site pain, abdominal pain | Injection site pain, muscle pain, headache, fever, and fatigue |
N/A, not applicable
*Included both children aged 12–17 years and adults